

# Yongge Liu

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4302443/yongge-liu-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

36

papers

3,628

citations

28

h-index

36

g-index

36

ext. papers

3,862

ext. citations

7.6

avg, IF

4.62

L-index

#	Paper	IF	Citations
36	Sputum lipoarabinomannan (LAM) as a biomarker to determine sputum mycobacterial load: exploratory and model-based analyses of integrated data from four cohorts.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 327	4	0
35	Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 65,	5.9	6
34	Lipoarabinomannan in sputum to detect bacterial load and treatment response in patients with pulmonary tuberculosis: Analytic validation and evaluation in two cohorts. <i>PLoS Medicine</i> , <b>2019</b> , 16, e1002780	11.6	17
33	Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. <i>Tuberculosis</i> , <b>2018</b> , 108, 186-194	2.6	62
32	Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). <i>Tuberculosis</i> , <b>2018</b> , 111, 20-30	2.6	54
31	MIC of Delamanid (OPC-67683) against Mycobacterium tuberculosis Clinical Isolates and a Proposed Critical Concentration. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3316-22	5.9	39
30	Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. <i>Cardiovascular Drugs and Therapy</i> , <b>2013</b> , 27, 109-15	3.9	46
29	Platelet P2Y <sub>1</sub> blockers confer direct postconditioning-like protection in reperfused rabbit hearts. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2013</b> , 18, 251-62	2.6	115
28	Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle. <i>Circulation Journal</i> , <b>2010</b> , 74, 181-7	2.9	10
27	Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning. <i>Basic Research in Cardiology</i> , <b>2010</b> , 105, 119-28	11.8	34
26	Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. <i>Cellular Signalling</i> , <b>2007</b> , 19, 1765-71	4.9	74
25	The Fab fragment of a novel anti-GPVI monoclonal antibody, OM4, reduces in vivo thrombosis without bleeding risk in rats. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 1199-205	9.4	56
24	Antiplatelet and antithrombotic activity of cilostazol is potentiated by dipyridamole in rabbits and dissociated from bleeding time prolongation. <i>Cardiovascular Drugs and Therapy</i> , <b>2005</b> , 19, 41-8	3.9	7
23	Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. <i>Platelets</i> , <b>2004</b> , 15, 167-72	3.6	36
22	Cilostazol and dipyridamole synergistically inhibit human platelet aggregation. <i>Journal of Cardiovascular Pharmacology</i> , <b>2004</b> , 44, 266-73	3.1	14
21	Cilostazol as a unique antithrombotic agent. <i>Current Pharmaceutical Design</i> , <b>2003</b> , 9, 2289-302	3.3	151
20	Cytoprotective role of Ca <sup>2+</sup> - activated K <sup>+</sup> channels in the cardiac inner mitochondrial membrane. <i>Science</i> , <b>2002</b> , 298, 1029-33	33.3	395

19	Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. <i>Cardiovascular Drugs and Therapy</i> , <b>2002</b> , 16, 417-27	3.9	55
18	New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. <i>Journal of Cardiovascular Pharmacology</i> , <b>2002</b> , 40, 577-85	3.1	36
17	Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. <i>Cardiovascular Drug Reviews</i> , <b>2001</b> , 19, 369-86		141
16	Opening of mitochondrial K(ATP) channels triggers cardioprotection. Are reactive oxygen species involved?. <i>Circulation Research</i> , <b>2001</b> , 88, 750-2	15.7	25
15	Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. <i>Journal of Cardiovascular Pharmacology</i> , <b>2001</b> , 38, 775-83	3.1	31
14	Mitochondrial ATP-sensitive K <sup>+</sup> channels play a role in cardioprotection by Na <sup>+</sup> -H <sup>+</sup> exchange inhibition against ischemia/reperfusion injury. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 957-63	15.1	53
13	Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 238-45	15.1	85
12	Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. <i>Journal of Cardiovascular Pharmacology</i> , <b>2000</b> , 36, 351-60	3.1	55
11	Mitochondrial ATP-dependent potassium channels. Viable candidate effectors of ischemic preconditioning. <i>Annals of the New York Academy of Sciences</i> , <b>1999</b> , 874, 27-37	6.5	121
10	Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. <i>Journal of Cardiovascular Pharmacology</i> , <b>1999</b> , 34, 497-504	3.1	88
9	Suppression of KATP currents by gene transfer of a dominant negative Kir6.2 construct. <i>Pflugers Archiv European Journal of Physiology</i> , <b>1998</b> , 436, 957-61	4.6	16
8	Mitochondrial ATP-dependent potassium channels: novel effectors of cardioprotection?. <i>Circulation</i> , <b>1998</b> , 97, 2463-9	16.7	708
7	Selective effects of oxygen free radicals on excitation-contraction coupling in ventricular muscle. Implications for the mechanism of stunned myocardium. <i>Circulation</i> , <b>1996</b> , 94, 2597-604	16.7	107
6	Phospholipase D plays a role in ischemic preconditioning in rabbit heart. <i>Circulation</i> , <b>1996</b> , 94, 1713-8	16.7	69
5	Synergistic modulation of ATP-sensitive K <sup>+</sup> currents by protein kinase C and adenosine. Implications for ischemic preconditioning. <i>Circulation Research</i> , <b>1996</b> , 78, 443-54	15.7	119
4	Intrinsic myofilament alterations underlying the decreased contractility of stunned myocardium. A consequence of Ca <sup>2+</sup> -dependent proteolysis?. <i>Circulation Research</i> , <b>1996</b> , 78, 455-65	15.7	113
3	Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. <i>Circulation Research</i> , <b>1995</b> , 77, 611-21	15.7	363
2	Chelerythrine, a highly selective protein kinase C inhibitor, blocks the anti-infarct effect of ischemic preconditioning in rabbit hearts. <i>Cardiovascular Drugs and Therapy</i> , <b>1994</b> , 8, 881-2	3.9	58

- 1 Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. *Journal of Molecular and Cellular Cardiology*, **1994**, 26, 661-8 5.8 269